FDA Approves Finerenone for Chronic Kidney Disease: 18% Risk Reduction in FIDELIO-DKD Trial

Executive Brief

News Report

The News: FDA approves finerenone for chronic kidney disease in type 2 diabetes.
Clinical Win: Finerenone shows significant reduction in kidney function decline and cardiovascular events.
Target Specialty: Nephrology

Key Data at a Glance

Composite endpoint reduction: 18%
Trial enrollment: 5,674 patients
Event rates for finerenone: 17.7%
Event rates for placebo: 21.1%

The FDA has approved finerenone (Kerendia) to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. This approval is significant as diabetes is the leading cause of chronic kidney disease and kidney failure in the United States, highlighting the urgent need for effective treatments. The announcement was made on July 9, 2021.

Clinical Context

Chronic kidney disease (CKD) is a progressive condition characterized by the gradual loss of kidney function, often leading to kidney failure, which necessitates dialysis or transplantation for survival. The prevalence of CKD is increasing globally, with diabetes being the most common underlying cause. Patients with CKD often experience a range of complications, including cardiovascular disease, which is a leading cause of morbidity and mortality in this population. Current treatment options primarily focus on managing blood pressure and controlling blood glucose levels, but there remains a significant gap in therapies that directly address the progression of kidney disease and its associated cardiovascular risks. The FIDELIO-DKD trial evaluated the efficacy of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in improving kidney and heart outcomes in patients with CKD and type 2 diabetes.

Key Findings

The trial enrolled 5,674 adults with chronic kidney disease associated with type 2 diabetes [1].

Event rates: 17.7% of patients receiving finerenone experienced the composite endpoint versus 21.1% in the placebo group [1].

The primary endpoint was a composite of time to first occurrence of at least a 40% reduction in eGFR, end-stage kidney disease, or kidney-related death [1].

Safety & Tolerability

The FIDELIO-DKD trial showed finerenone reduced the risk of a composite endpoint of at least a 40% reduction in kidney function, progression to kidney failure, or kidney death by 18% versus placebo (HR 0.82; 95% CI 0.73-0.93) [1].

What This Means for Clinical Practice

Finerenone is indicated for use in patients with chronic kidney disease associated with type 2 diabetes, providing an important new option for clinicians managing this high-risk population. The 18% reduction in the composite risk of kidney function decline and cardiovascular events supports its integration into treatment plans for patients at risk of CKD progression. Clinicians should consider finerenone as part of a comprehensive approach that includes lifestyle modifications and standard diabetes management. As the understanding of CKD continues to evolve, the incorporation of finerenone into clinical practice may help mitigate the risks associated with kidney disease and improve overall patient outcomes.

The approval of finerenone also raises questions about how it will be incorporated into existing treatment guidelines and the long-term implications for patient care in nephrology. Further studies may be needed to assess its effectiveness in diverse populations and its role in combination therapies for diabetes-related kidney disease.

Clinical Perspective

Workflow: The approval of finerenone allows nephrologists to offer a new therapeutic option for patients with CKD and type 2 diabetes.

Economics: With the rising prevalence of CKD, incorporating finerenone may help reduce long-term healthcare costs associated with kidney failure.

Patient Outcomes: Finerenone's efficacy in reducing kidney disease progression may lead to improved quality of life and reduced hospitalization rates for patients.

Dr. Praveen Singh, Nephrology

References

FDA — FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes